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Editorial

Do we need to worry about
mycophenolate overdose?
Guido Filler† & Amaryllis Ferrand
†

University of Western Ontario, Children’ s Hospital, London Health Sciences Centre,
Department of Paediatrics, Ontario, Canada

Introduction: To discuss the significance of the recent observational case series
from the Swiss Toxicological Information Centre (STIC). Mycophenolic acid
(MPA) and its prodrug mycophenolate mofetil are immunosuppressive agents
that are frequently prescribed in renal transplant recipients, and their safety
profiles must be established.
Areas covered: This case series and systemic literature analysis consists
of 15 cases of MPA overdose from the STIC and a systemic analysis of the
literature over the past 18 years. This study focuses on acute overdosing, the
effects of which are presumably mild. In contrast, the effects of long-term
overdosing may be much more severe. Substantial underreporting is likely.
The pharmacokinetic monitoring of MPA is rarely performed, which is both
striking and does not coincide with findings in academic literature. The scant
data on pharmacokinetic monitoring presented demonstrated that MPA has a
short terminal half-life, which suggests that decontamination and activated
charcoal treatment in acute overdose may not be necessary.
Expert opinion: The case series and systematic literature analysis of acute
mycophenolate overdose represent an important contribution toward
increasing the safety of MPA therapy.
Keywords: human toxicity, mycophenolate mofetil, mycophenolate sodium,
mycophenolic acid, overdose
Expert Opin. Drug Saf. (2014) 13(5):521-524

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is the
most widely prescribed immunosuppressive agent for preventing rejection following
kidney transplantation in many countries [1]. Up to 80% of transplant recipients
undergo long-term therapy using some form of MPA.
Both MMF and enteric-coated mycophenolate sodium (EC-MPS) therapy are
associated with frequent adverse drug reactions (‡ 1% of patients) that include
diarrhea, nausea, vomiting, infections, leukopenia and/or anemia. Other adverse
events include fatigue, headache and/or cough. Less frequent adverse effects
(0.1 -- 1% of patients) include esophagitis, gastritis, gastrointestinal tract hemorrhage and/or invasive cytomegalovirus (CMV) infection. Intravenous (i.v.) administration of MMF is commonly associated with thrombophlebitis and thrombosis.
The US FDA recently issued an alert concerning the increased risk of developing
opportunistic infections in patients taking MMF and MPA, particularly new or
reactivated viral infections, including shingles, other herpes infections, CMV, and
BK virus-associated nephropathy. Moreover, the FDA is currently investigating
17 cases of progressive multifocal leukoencephalopathy, a rare and usually fatal
neurological disease, which developed in patients taking the drug [2].
Literature describing the acute toxicity of MPA is sparse. MPA can be
administered either intravenously or orally, with the latter being available in various formulations such as the prodrug MMF or as mycophenolate sodium. In fact,
although there is a substantial amount of evidence supporting considerable
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interpatient and intrapatient variability in responses to the
drug [3,4]; manufacturer guidelines endorse fixed dosing.
In this edition of Expert Opinion on Drug Safety, we
are delighted to see a systematic analysis of all reported
acute overdoses from the Swiss Toxicological Information
Center (STIC) as well as a literature review of MPA overdose
cases over an 18-year period [5]. Most adult cases occurred
as a result of attempted suicide, whereas children were
subject to accidental poisoning in the home. The authors
should be congratulated for this work as it includes all
available data, including the sparsely available pharmacokinetic monitoring data suggesting that MPA has a short
terminal half-life (between 2.6 and 7.4 h). Although most
of the symptoms were mild and included abdominal pain,
vomiting, headache, dizziness and/or a drop in blood
pressure, they worsened in a dose-dependent manner. The
authors clearly discuss limitations and emphasize the issue
of underreporting.
MPA is available as i.v. MMF, as oral MMF and now as
non-innovator generic formulations, such as the Teva formulation [6]. It is also available as EC-MPS. Most of the reports
in the STIC database involve MMF.
One of the striking findings this manuscript highlights is
the paucity of data surrounding the monitoring of MPA blood
levels in these patients. The clinical utility of therapeutic drug
monitoring of MPA is still controversial. However, the
pharmacokinetics of MMF is highly variable [3,4]. This can
be attributed to drug--drug interactions between MMF and
both of the calcineurin inhibitors (cyclosporine or tacrolimus [7]) and with steroids [8]. Cyclosporine augments MPA
clearance, whereas tacrolimus may reduce it. Ontogeny of
drug disposition [9] and variable degrees of renal impairment [10]
also significantly contribute to the substantial interpatient variability, which can reach 100%. There is good evidence that an
AUC > 30 mg  h/l is required to prevent rejection [11].
Recent consensus guidelines have, therefore, increased the
dosing recommendation depending on the concomitant calcineurin inhibitor being administered to avoid underdosing [3,4].
The upper therapeutic window of MPA is not as well defined,
and limited sampling strategies are necessary to determine
AUC as there is poor correlation between the trough level
and the AUC [12]. It should be pointed out that these limited
sampling strategies only apply for the oral MMF. The pharmacokinetics of MMF and EC-MPS are very different [13].
Limited sampling strategies for EC-MPS vary in estimating
AUC [14,15].
Other advantages of therapeutic drug monitoring of MPA
include safer therapy in patients who are treated with
protocols that explore calcineurin inhibitor minimization,
withdrawal or even complete avoidance. This also applies to
steroid withdrawal or steroid avoidance regimens. These
patients might, therefore, benefit from therapeutic drug
monitoring of MPA, especially when unexplained side effects
occur. MPA pharmacokinetic monitoring may also help in
identifying nonadherence in the adolescent population.
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A recent crossover study comparing equivalent exposure of
MMF with two different formulations of tacrolimus suggests
a high prevalence of both underdosing and overdosing [16].
Despite this evidence, MMF and EC-MPS therapies are not
usually subject to pharmacokinetic monitoring, as is clearly
indicated by the authors of the study addressed in this
editorial. Pharmacokinetic monitoring is widely available,
either through immunological assays such as the EMIT 2000
MPA assay from Siemens Healthcare, Inc., through the
high-performance liquid chromatography reference method
or through mass spectrometry -- the most cost-effective
method.
The substantial prevalence of underreporting should be
emphasized, since it may suggest that side effects are usually
mild. MPA is commonly administered concomitantly with
multiple agents, and it is these other medications that may
be causing adverse events. As MMF is the single-most
commonly prescribed immunosuppressant for renal transplantation in the pediatric population in North America [17],
it is critically important that physicians be mindful of
overdosing. This is especially crucial in children who require
life-long immunosuppression since they are at a substantially
higher risk of malignancies such as post-transplant lymphoproliferative disease and other forms of cancer [18]. In the
article, patients were only subject to overdosing for a
maximum of 5 days. This may explain why there was only
one case of myelosuppression. Given the relationship between
drug exposure and myelosuppression, and the prevalence of
myelosuppression in patients who have undergone transplantation, there are most likely more cases of overdosing that go
unnoticed [3]. We were able to identify the extent of overdosing in our own case report (included in the study) because of
pharmacokinetic monitoring [19].
In view of the benefits of pharmacokinetic monitoring of
MPA for MMF or EC-MPS therapy, which was omitted in
most of the cases reported by the manuscript, the infrequent
use of this clinical tool is surprising. Although there is good
evidence showing that a minimum AUC of 30 mg  h/l
prevents rejection, there is a complete lack of good data
defining the upper limit of the therapeutic window,
especially as the resurgence of viral illnesses increases with
increasing exposure to the agent. We would like to draw
attention to the possibility that many patients are being
treated with doses surpassing the therapeutic level for a
prolonged period of time, and that this goes unnoticed
because of a lack of pharmacokinetic monitoring. Chronic
overdosing may have far more serious effects than the acute
short-term overdosing as described by the authors. Further,
as renal function often declines following renal transplantation and as retransplantation is often necessary, monitoring
the accumulation of the main glucuronide metabolite,
MPA-G, may become increasingly important with worsening renal function. MPA-G is formed in the liver, excreted
in the bile and subjected to enterohepatic recirculation
and renal excretion [10].
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Conclusion
We would like to congratulate the authors of the recent
manuscript in Expert Opinion on Drug Safety once more for
their important work. We agree that more data are needed
to determine the effects of decontamination and activated
charcoal treatment. The relatively short half-life of MPA suggests that charcoal treatment may not be necessary in patients
with reasonably good kidney function. Cognizance of the
effects of and consequent avoidance of acute and chronic
overdosing is of particular importance in young patients
requiring life-long immunosuppression. Pharmacokinetic
monitoring of MPA in patients receiving MMF or EC-MPS
therapy should be encouraged, and the upper limit of the
therapeutic window should be more clearly defined. This
may be especially true in view of the recent FDA warning
concerning new or reactivated viral infections which can be
associated with a fatal neurological disease. The manuscript
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